Last updated: 2026-09-09 05:05:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aspire Biopharma Holdings, Inc. (ASBP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.91, with a market capitalization of $12.44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.31 to $659.40. This page covers its latest market performance, valuation, price trends and company information.
$12.44M | |
$8.89 | |
$35,088.00 | |
$3.31 | |
-- | |
8.59K | |
274.20K | |
-- | |
$659.40 | |
$3.31 | |
-- | |
-- |
Aspire Biopharma Holdings, Inc. (ASBP) last closed at $0.00 as of 2026-09-08 23:54:00, -- from the previous close of $0.00.
During the latest regular trading session, ASBP traded between $3.31 and $35,088.00, with a volume of 8.59K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Aspire Biopharma Holdings, Inc. (ASBP) moved from $8.26 to $8.91, representing a gain of 7.88% ($0.65).
The stock traded between $8.07 and $9.50 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 31.56 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.9%
ASBP is currently trading at $8.91, placing it 0.9% of the way from its 52-week low of $3.31 to its 52-week high of $659.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aspire Biopharma Holdings, Inc. (ASBP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.